Very Complex karyotype is an inclusion criterion in 128 clinical trials for acute myeloid leukemia, of which 99 are open and 29 are closed. Of the trials that contain Very Complex karyotype and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (2 open), 34 are phase 1 (24 open), 26 are phase 1/phase 2 (20 open), 51 are phase 2 (42 open), 3 are phase 2/phase 3 (3 open), 9 are phase 3 (6 open), and 3 are no phase specified (2 open) [5].

Fludarabine, cyclophosphamide, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in trials for acute myeloid leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 99 clinical trials for myelodysplastic syndromes, of which 85 are open and 14 are closed. Of the trials that contain Very Complex karyotype and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (2 open), 25 are phase 1 (20 open), 18 are phase 1/phase 2 (16 open), 41 are phase 2 (36 open), 2 are phase 2/phase 3 (2 open), 7 are phase 3 (6 open), and 4 are no phase specified (3 open) [5].

Fludarabine, cyclophosphamide, and azacitidine are the most frequent therapies in trials for myelodysplastic syndromes that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 51 clinical trials for acute lymphoblastic leukemia, of which 41 are open and 10 are closed. Of the trials that contain Very Complex karyotype and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 13 are phase 1 (8 open), 7 are phase 1/phase 2 (5 open), 25 are phase 2 (22 open), 1 is phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 2 are no phase specified (2 open) [5].

Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in trials for acute lymphoblastic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 34 clinical trials for chronic myeloid leukemia, of which 28 are open and 6 are closed. Of the trials that contain Very Complex karyotype and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 10 are phase 1 (6 open), 5 are phase 1/phase 2 (5 open), 16 are phase 2 (14 open), and 2 are no phase specified (2 open) [5].

Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in trials for chronic myeloid leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 25 clinical trials for chronic myelomonocytic leukemia, of which 20 are open and 5 are closed. Of the trials that contain Very Complex karyotype and chronic myelomonocytic leukemia as inclusion criteria, 5 are phase 1 (4 open), 6 are phase 1/phase 2 (5 open), 11 are phase 2 (9 open), and 3 are phase 3 (2 open) [5].

Fludarabine, allogeneic hematopoietic stem cell transplantation, and azacitidine are the most frequent therapies in trials for chronic myelomonocytic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 20 clinical trials for multiple myeloma, of which 17 are open and 3 are closed. Of the trials that contain Very Complex karyotype and multiple myeloma as inclusion criteria, 6 are phase 1 (4 open), 1 is phase 1/phase 2 (0 open), 11 are phase 2 (11 open), and 2 are no phase specified (2 open) [5].

Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in trials for multiple myeloma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 19 clinical trials for hodgkin lymphoma, of which 14 are open and 5 are closed. Of the trials that contain Very Complex karyotype and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is no phase specified (1 open) [5].

Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in trials for hodgkin lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 19 clinical trials for non-hodgkin lymphoma, of which 14 are open and 5 are closed. Of the trials that contain Very Complex karyotype and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), 10 are phase 2 (9 open), and 1 is no phase specified (1 open) [5].

Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in trials for non-hodgkin lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 14 clinical trials for acute biphenotypic leukemia, of which 8 are open and 6 are closed. Of the trials that contain Very Complex karyotype and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 6 are phase 2 (4 open), 1 is phase 3 (0 open), and 1 is no phase specified (1 open) [5].

Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in trials for acute biphenotypic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 13 clinical trials for chronic lymphocytic leukemia, of which 10 are open and 3 are closed. Of the trials that contain Very Complex karyotype and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [5].

Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in trials for chronic lymphocytic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 12 clinical trials for acute leukemia, of which 11 are open and 1 is closed. Of the trials that contain Very Complex karyotype and acute leukemia as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 6 are phase 2 (6 open), and 1 is no phase specified (1 open) [5].

Fludarabine, mycophenolate mofetil, and cyclophosphamide are the most frequent therapies in trials for acute leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 12 clinical trials for Burkitt lymphoma, of which 11 are open and 1 is closed. Of the trials that contain Very Complex karyotype and Burkitt lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (6 open), and 2 are no phase specified (2 open) [5].

Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in trials for Burkitt lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 11 clinical trials for mantle cell lymphoma, of which 10 are open and 1 is closed. Of the trials that contain Very Complex karyotype and mantle cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 6 are phase 2 (6 open), and 2 are no phase specified (2 open) [5].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in trials for mantle cell lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 11 clinical trials for myeloproliferative neoplasm, of which 10 are open and 1 is closed. Of the trials that contain Very Complex karyotype and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (6 open), and 2 are no phase specified (2 open) [5].

Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in trials for myeloproliferative neoplasm that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 10 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 10 are open and 0 are closed. Of the trials that contain Very Complex karyotype and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (7 open), and 2 are no phase specified (2 open) [5].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in trials for chronic lymphocytic leukemia/small lymphocytic lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 10 clinical trials for follicular lymphoma, of which 10 are open and 0 are closed. Of the trials that contain Very Complex karyotype and follicular lymphoma as inclusion criteria, 2 are phase 1 (2 open), 6 are phase 2 (6 open), and 2 are no phase specified (2 open) [5].

Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in trials for follicular lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 10 clinical trials for marginal zone lymphoma, of which 10 are open and 0 are closed. Of the trials that contain Very Complex karyotype and marginal zone lymphoma as inclusion criteria, 2 are phase 1 (2 open), 6 are phase 2 (6 open), and 2 are no phase specified (2 open) [5].

Fludarabine, cyclophosphamide, and mycophenolate mofetil are the most frequent therapies in trials for marginal zone lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 9 clinical trials for anaplastic large cell lymphoma, of which 9 are open and 0 are closed. Of the trials that contain Very Complex karyotype and anaplastic large cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 2 are no phase specified (2 open) [5].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in trials for anaplastic large cell lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 4 are open and 3 are closed. Of the trials that contain Very Complex karyotype and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

Cyclophosphamide, allogeneic hematopoietic stem cell transplantation, and tacrolimus are the most frequent therapies in trials for juvenile myelomonocytic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 7 clinical trials for lymphoma, of which 6 are open and 1 is closed. Of the trials that contain Very Complex karyotype and lymphoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [5].

Total-body irradiation, cyclophosphamide, and fludarabine are the most frequent therapies in trials for lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 7 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 6 are open and 1 is closed. Of the trials that contain Very Complex karyotype and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [5].

Cyclophosphamide, total-body irradiation, and fludarabine are the most frequent therapies in trials for myelodysplastic/myeloproliferative neoplasm that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 7 clinical trials for myelofibrosis, of which 6 are open and 1 is closed. Of the trials that contain Very Complex karyotype and myelofibrosis as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (3 open) [5].

Fludarabine, cyclophosphamide, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in trials for myelofibrosis that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 7 clinical trials for prolymphocytic leukemia, of which 7 are open and 0 are closed. Of the trials that contain Very Complex karyotype and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 2 are no phase specified (2 open) [5].

Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in trials for prolymphocytic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 6 clinical trials for lymphoplasmacytic lymphoma, of which 6 are open and 0 are closed. Of the trials that contain Very Complex karyotype and lymphoplasmacytic lymphoma as inclusion criteria, 4 are phase 2 (4 open) and 2 are no phase specified (2 open) [5].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in trials for lymphoplasmacytic lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 5 clinical trials for plasma cell leukemia, of which 4 are open and 1 is closed. Of the trials that contain Very Complex karyotype and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 2 (3 open), and 1 is no phase specified (1 open) [5].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in trials for plasma cell leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 5 clinical trials for small lymphocytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain Very Complex karyotype and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

Fludarabine, mycophenolate mofetil, and tacrolimus are the most frequent therapies in trials for small lymphocytic lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain Very Complex karyotype and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [5].

Bet inhibitor ft-1101, cdk9 inhibitor azd4573, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in trials for B-cell non-hodgkin lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 0 are closed. Of the trials that contain Very Complex karyotype and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [5].

Allogeneic hematopoietic stem cell transplantation, antineoplastic immune cell, and bet inhibitor ft-1101 are the most frequent therapies in trials for diffuse large B-cell lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain Very Complex karyotype and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

Fludarabine, tacrolimus, and rituximab are the most frequent therapies in trials for double-hit lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 4 clinical trials for lymphoblastic lymphoma, of which 4 are open and 0 are closed. Of the trials that contain Very Complex karyotype and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [5].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in trials for lymphoblastic lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 4 clinical trials for refractory anemia with excess blasts, of which 3 are open and 1 is closed. Of the trials that contain Very Complex karyotype and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [5].

Azacitidine, autologous nkg2d car-expressing t-lymphocytes cm-cs1, and prima-1 analog apr-246 are the most frequent therapies in trials for refractory anemia with excess blasts that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 3 clinical trials for primary myelofibrosis, of which 2 are open and 1 is closed. Of the trials that contain Very Complex karyotype and primary myelofibrosis as inclusion criteria, 3 are phase 2 (2 open) [5].

Fludarabine, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in trials for primary myelofibrosis that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 3 are open and 0 are closed. Of the trials that contain Very Complex karyotype and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (3 open) [5].

Cyclophosphamide, fludarabine, and mesna are the most frequent therapies in trials for T-cell lymphoblastic leukemia/lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 3 clinical trials for T-cell non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain Very Complex karyotype and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

Cdk9 inhibitor azd4573, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in trials for T-cell non-hodgkin lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for acute leukemia of ambiguous lineage, of which 2 are open and 0 are closed. Of the trials that contain Very Complex karyotype and acute leukemia of ambiguous lineage as inclusion criteria, 2 are phase 2 (2 open) [5].

Cyclosporine, mycophenolate mofetil, and hematopoietic progenitor cells from cord blood are the most frequent therapies in trials for acute leukemia of ambiguous lineage that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for acute promyelocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain Very Complex karyotype and acute promyelocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (1 open) [5].

Anti-cd123 adc imgn632, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in trials for acute promyelocytic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain Very Complex karyotype and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [5].

Blinatumomab, cyclophosphamide, and cytarabine are the most frequent therapies in trials for B-cell acute lymphoblastic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for blastic plasmacytoid dendritic cell neoplasm, of which 2 are open and 0 are closed. Of the trials that contain Very Complex karyotype and blastic plasmacytoid dendritic cell neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

Anti-cd123 adc imgn632, cyclosporine, and filgrastim are the most frequent therapies in trials for blastic plasmacytoid dendritic cell neoplasm that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain Very Complex karyotype and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [5].

Busulfan, cyclophosphamide, and fludarabine are the most frequent therapies in trials for Burkitt leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for hematopoietic and lymphoid malignancy, of which 2 are open and 0 are closed. Of the trials that contain Very Complex karyotype and hematopoietic and lymphoid malignancy as inclusion criteria, 2 are phase 2 (2 open) [5].

Fludarabine, thiotepa, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in trials for hematopoietic and lymphoid malignancy that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain Very Complex karyotype and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open) [5].

Busulfan, cyclophosphamide, and fludarabine are the most frequent therapies in trials for malignant solid tumor that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 1 is open and 1 is closed. Of the trials that contain Very Complex karyotype and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [5].

Cyclophosphamide, fludarabine, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in trials for mature T-cell and NK-cell lymphoma/leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 2 are open and 0 are closed. Of the trials that contain Very Complex karyotype and mature T-cell and NK-cell neoplasm as inclusion criteria, 2 are phase 2 (2 open) [5].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in trials for mature T-cell and NK-cell neoplasm that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain Very Complex karyotype and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open) [5].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in trials for mature T-cell and NK-cell non-hodgkin lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for myeloid sarcoma, of which 2 are open and 0 are closed. Of the trials that contain Very Complex karyotype and myeloid sarcoma as inclusion criteria, 2 are phase 2 (2 open) [5].

Fludarabine, non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, and sorafenib are the most frequent therapies in trials for myeloid sarcoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 2 are open and 0 are closed. Of the trials that contain Very Complex karyotype and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

Cyclophosphamide, mesna, and non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation are the most frequent therapies in trials for natural killer cell lymphoblastic leukemia/lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain Very Complex karyotype and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

Allogeneic hematopoietic stem cell transplantation, antineoplastic immune cell, and autologous hematopoietic stem cell transplatation are the most frequent therapies in trials for peripheral T-cell lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for refractory anemia, of which 1 is open and 1 is closed. Of the trials that contain Very Complex karyotype and refractory anemia as inclusion criteria, 2 are phase 2 (1 open) [5].

Deferasirox, stemregenin-1 expanded umbilical cord blood transplant, and cytarabine are the most frequent therapies in trials for refractory anemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for refractory anemia with excess blasts-2, of which 0 are open and 2 are closed. Of the trials that contain Very Complex karyotype and refractory anemia with excess blasts-2 as inclusion criteria, 2 are phase 2 (0 open) [5].

Cytarabine, hedgehog inhibitor pf-04449913, and stemregenin-1 expanded umbilical cord blood transplant are the most frequent therapies in trials for refractory anemia with excess blasts-2 that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 2 clinical trials for small lymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain Very Complex karyotype and small lymphocytic leukemia as inclusion criteria, 2 are phase 1 (1 open) [5].

Cdk9 inhibitor azd4573, busulfan, and clofarabine are the most frequent therapies in trials for small lymphocytic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in trials for acute erythroid leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in trials for acute megakaryoblastic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and rivogenlecleucel are the most frequent therapies in trials for acute myeloid leukemia with myelodysplasia-related changes that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for acute undifferentiated leukemia, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and acute undifferentiated leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

Non-myeloablative tcr alpha/beta-depleted haploidentical hematopoietic stem cell transplantation, rabbit anti-thymocyte globulin, and cyclophosphamide are the most frequent therapies in trials for acute undifferentiated leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in trials for adult acute lymphoblastic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (1 open) [5].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in trials for adult T-cell leukemia/lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for aggressive non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and aggressive non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Cyclosporine, filgrastim, and mycophenolate mofetil are the most frequent therapies in trials for aggressive non-hodgkin lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for B-cell prolymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in trials for B-cell prolymphocytic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-1, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and chronic myelomonocytic leukemia-1 as inclusion criteria, 1 is phase 2 (1 open) [5].

Deferasirox is the most frequent therapy in trials for chronic myelomonocytic leukemia-1 that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains Very Complex karyotype and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

Allogeneic cd56-positive cd3-negative natural killer cells, allogeneic hematopoietic stem cell transplantation, and chemotherapy are the most frequent therapies in trials for desmoplastic small round cell tumor that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains Very Complex karyotype and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

Allogeneic cd56-positive cd3-negative natural killer cells, allogeneic hematopoietic stem cell transplantation, and chemotherapy are the most frequent therapies in trials for Ewing sarcoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

Bet inhibitor ft-1101 and azacitidine are the most frequent therapies in trials for mature B-cell lymphoma/leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Bet inhibitor ft-1101 and azacitidine are the most frequent therapies in trials for mediastinal large B-cell lymphoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

Allogeneic bone marrow transplantation, busulfan, and cyclophosphamide are the most frequent therapies in trials for mixed phenotype acute leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for myeloma, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in trials for myeloma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains Very Complex karyotype and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

Allogeneic cd56-positive cd3-negative natural killer cells, allogeneic hematopoietic stem cell transplantation, and chemotherapy are the most frequent therapies in trials for neuroblastoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains Very Complex karyotype and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in trials for plasma cell neoplasm that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [5].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in trials for polycythemia vera that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for refractory anemia with ring sideroblasts, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and refractory anemia with ring sideroblasts as inclusion criteria, 1 is phase 2 (1 open) [5].

Deferasirox is the most frequent therapy in trials for refractory anemia with ring sideroblasts that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains Very Complex karyotype and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

Allogeneic cd56-positive cd3-negative natural killer cells, allogeneic hematopoietic stem cell transplantation, and chemotherapy are the most frequent therapies in trials for rhabdomyosarcoma that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and Richter syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

Cdk9 inhibitor azd4573 is the most frequent therapy in trials for Richter syndrome that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

Ect-001 expanded cord blood is the most frequent therapy in trials for secondary acute myeloid leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [5].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in trials for secondary myelodysplastic syndrome that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for secondary myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains Very Complex karyotype and secondary myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 3 (1 open) [5].

Cyclophosphamide, cytarabine, and daunorubicin are the most frequent therapies in trials for T-cell acute lymphoblastic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains Very Complex karyotype and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [5].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in trials for T-cell prolymphocytic leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

Anti-thymocyte globulin, cyclophosphamide, and fludarabine are the most frequent therapies in trials for T-cell and NK-cell neoplasm that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

Ect-001 expanded cord blood is the most frequent therapy in trials for therapy-related acute myeloid leukemia that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for therapy-related myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and therapy-related myeloid neoplasm as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

Family-mismatched/haploidentical donor, mismatched unrelated donor, and peripheral blood stem cell transplantation are the most frequent therapies in trials for therapy-related myeloid neoplasm that contain Very Complex karyotype [5].

Very Complex karyotype is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains Very Complex karyotype and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [5].

Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most frequent therapies in trials for waldenstrom macroglobulinemia that contain Very Complex karyotype [5].